Все публикации

1:29:34

Exploring non-traditional antimicrobials: Insights from three cases

0:47:00

The value of surveillance data in defining the medical need for new antimicrobials

1:27:10

Progressing a discovery project – Criteria and challenges

0:01:16

Difficult-to-treat resistance (DTR)

0:57:52

What does the future look like if pull incentives to support antibiotic R&D are insufficient?

1:02:01

SECURE: Improving access to antibiotics through new economic models

1:23:29

What do the various non-commercial actors in the antibiotic R&D ecosystem do?

0:02:29

Putting public health needs at the centre of antibiotic drug development

0:02:23

Endpoints for antibacterial trials: microbiologic

0:01:57

Endpoints for antibacterial trials: timing of assessments

0:59:42

GARDP: An innovative public health approach to counter AMR

0:02:57

GARDP - Celebrating 5 years

0:02:26

Exploring opportunities to improve the treatment of gonorrhoea in Thailand

0:01:44

The fight against drug resistant gonorrhoea

0:02:26

Staying one step ahead of the bug

0:03:37

Lead optimization

1:00:15

Market interventions to improve access to antibiotics for resistant infections

0:02:27

Research brings hope for better antibiotic treatment for babies

0:59:11

Antibiotic shortages causes, consequences, and solutions

1:14:40

Clinical trial platforms for new and neglected antimicrobials

1:22:55

Starting an antibacterial drug discovery screening programme

1:23:10

Antimicrobial drug discovery: SAR optimization and QSAR

0:02:31

Lifesaving treatment for neonatal sepsis in Uganda

0:01:59

Adverse event / Serious Adverse event